Genetic Technologies’ $6.56 Million Shares Offering

Sichenzia Ross Ference LLP represented Genetic Technologies Limited in the offering.

Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, completed a registered direct offering of 1,250,000 American Depositary Shares (ADSs), each representing 600 of the Company’s ordinary shares, at a purchase price of $5.25 per ADS.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The Sichenzia Ross Ference LLP team for Genetic Technologies was led by partners Darrin M. Ocasio (Picture), Avital Perlman and Jeffrey Cahlon and associate Yian Pan.

Involved fees earner: Jeffrey Cahlon – Sichenzia Ross Ference LLP; Darrin Ocasio – Sichenzia Ross Ference LLP; Yian Pan – Sichenzia Ross Ference LLP; Avital Perlman – Sichenzia Ross Ference LLP;

Law Firms: Sichenzia Ross Ference LLP;

Clients: Genetic Technologies Ltd;


Author: Ambrogio Visconti